This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G12.1 | Special Copayment Reduction: V123 | Coverage period: 5 years |
| B. Synonyms | Progressive bulbar palsy of childhood [Fazio-Londe], distal spinal muscular atrophy, scapuloperoneal spinal muscular atrophy, childhood type II spinal muscular atrophy, juvenile type III [Kugelberg-Welander] spinal muscular atrophy, adult-type spinal muscular atrophy |
| C. Adult onset | Low to moderate likelihood of first onset in adulthood — SMA type III begins after 18 months, with some delayed until adolescence; SMA type IV (adult type) begins in adulthood |
| 1. History | After Werdnig-Hoffmann's description in the 1890s, Kugelberg-Welander and others established the classification of clinical types |
| 2. Causes | Survival motor neuron (SMN) protein deficiency due to SMN1 gene deletion or mutation |
| 3. Genetics | 5q13.2 SMN1, autosomal recessive; SMN2 copy number plays a major role in determining phenotype |
| 4. General epidemiology | About 1 per 10,000 births; prevalence 1–2 per 100,000 |
| 5. Pathophysiology | SMN protein deficiency → impaired snRNP assembly → selective death of motor neurons |
| 6. Symptoms | Symmetric proximal muscle weakness, flaccid paralysis, respiratory and swallowing impairment |
| 7. Signs | Loss of deep tendon reflexes, tongue fasciculations, spinal deformity |
| 8. Screening | Newborn screening (MLPA/qPCR), prenatal genetic testing when there is a family history |
| 9. Diagnosis | Genetic testing (MLPA, sequencing), electromyography, muscle biopsy, quantification of SMN2 copy number |
| 10. Treatment | Nusinersen (intrathecal), risdiplam (oral), onasemnogene (gene therapy); ventilatory support and rehabilitation |
| 11. Prognosis | Type II: unable to walk, shortened survival; type III: able to walk, life expectancy close to normal |
| 12. Prevention | Carrier screening, prenatal diagnosis, preimplantation genetic diagnosis (PGT) |
| 13. References | Mercuri E et al. Nat Rev Neurol 2022 and 9 other papers |
The clinical history of spinal muscular atrophy (SMA) dates back to the late 19th century. In 1891 the Austrian neurologist Guido Werdnig and in 1892 the German Hans Hoffmann independently described a severe form of SMA with onset in infancy, and this form was later named SMA type I (Werdnig-Hoffmann disease). In 1956, Erik Kugelberg and Lisa Welander of Sweden described a mild form of SMA with onset in adolescence, and this form became known as SMA type III or Kugelberg-Welander disease. In 1961, SMA type II (intermediate type, childhood-onset non-ambulatory type) was classified as a separate phenotype. In the early 1990s, the chromosome 5q13.2 region was identified as the SMA causative locus, and in 1995 Lefebvre and colleagues identified the SMN1 gene, opening a new era of molecular diagnosis. The SMN2 gene was discovered at the same time and was subsequently shown to play a key role in modulating phenotype. In 2016, nusinersen received FDA approval as the first SMA treatment, fundamentally transforming the treatment paradigm of SMA; risdiplam (oral) and onasemnogene abeparvovec (gene therapy) were subsequently approved in succession, and three disease-modifying therapies are now in clinical use. In Korea, nusinersen became covered by insurance in 2019, greatly improving access to treatment for SMA patients, and a nationwide real-world study (2024) has been published.
The direct cause of SMA types II and III is loss of function of the SMN1 (Survival Motor Neuron 1) gene located on chromosome 5q13.2. Homozygous deletion of SMN1 exons 7 and 8 is found in about 95% of all SMA patients, and the remaining about 5% show a compound heterozygous form with a deletion on one allele and a point mutation (missense, nonsense, splice-site, etc.) on the other. The SMN protein encoded by the SMN1 gene is essential for assembly of the spliceosomal small nuclear ribonucleoprotein (snRNP) complexes, and when this protein is deficient, motor neurons throughout the body become selectively vulnerable. The SMN2 gene is more than 99% identical in sequence to SMN1, but a single-nucleotide variant (C840T) in exon 7 causes exon 7 to be excluded from most transcripts, so mainly a short, functionally incomplete SMN△7 protein is produced. However, the higher the SMN2 copy number, the more full-length functional SMN protein is produced, albeit in small amounts, so SMN2 copy number acts as the key genetic modifier determining disease severity. SMA type II patients usually have 3 SMN2 copies, and SMA type III patients tend to have 3–4 copies. Environmental factors, epigenetic changes, and other protein modifiers (e.g., PLS3, NCALD) are also known to contribute to phenotypic diversity, but their clinical significance is still under study.
SMA follows an autosomal recessive inheritance pattern. The causative gene SMN1 is located on chromosome 5q13.2 and forms an inverted duplication structure with the adjacent SMN2, so recombination events such as duplication, deletion, and gene conversion occur frequently. In normal individuals, the standard is one SMN1 copy on each chromosome for a total of 2 copies, but some have a 2+0 carrier form with 2 SMN1 copies on one chromosome, which may be difficult to identify as carriers with standard MLPA testing. The carrier frequency is about 1/40–1/50, and the risk of SMA in a child born to two carriers is 25%. SMN2 copy number is important for predicting phenotype: 1 copy of SMN2 correlates with SMA type I (severe, stillbirth or neonatal death possible), 2 copies with SMA types I–II, 3 copies with SMA types II–III, and 4 or more copies with SMA types III–IV (mild) or asymptomatic status. However, SMN2 copy number alone cannot fully predict the phenotype of an individual patient, and additional genetic modifiers such as PLS3 (plastin 3) overexpression and NCALD underexpression can have a mitigating effect. Recent genome-wide association studies (GWAS) have proposed modifier loci other than SMN1/SMN2, and further research is ongoing. The recurrence risk within the family is 25% for siblings; children of patients are carriers, but this varies depending on SMN2 copy number.
SMA is the most common fatal autosomal recessive genetic disease after cystic fibrosis, with a worldwide birth prevalence of about 1/6,000–1/10,000. According to Korean data, it is at about 1 per 10,000 births, and the number of prevalent patients is estimated at about 500–700 (Rare Disease Helpline, 2023). SMA type I accounts for about 45–60% of the total, SMA type II about 20–30%, and SMA type III about 15–20%. SMA type IV (adult type) is less than 5% of all SMA. The carrier frequency differs little among ethnic groups and is consistently about 1/40–1/50. There is no sex bias, and it occurs in all ethnic groups. Epidemiological data from the era before treatments were introduced (before 2016) differ greatly from the present, and as newborn SMA screening becomes widespread, natural history–based prognostic data are changing rapidly owing to early diagnosis and treatment initiation. In Korea, SMA has been included in newborn screening since 2022, enabling early diagnosis. The male-to-female ratio is 1:1, and no regional clustering has been specifically reported. When there is a family history, prenatal genetic diagnosis can prevent occurrence in the next generation.
The core pathophysiology of SMA is selective degeneration of lower motor neurons due to SMN protein deficiency. In nuclear gems (Gemini of Cajal bodies), the SMN protein forms complexes with Sm proteins and small nuclear RNAs (snRNAs) to promote snRNP assembly, thereby enabling normal function of the spliceosome, which is essential for pre-mRNA splicing. When SMN is deficient, spliceosome dysfunction causes numerous mRNA splicing errors, and in particular abnormal processing of proteins needed by motor neurons accumulates, leading to neuronal death. The reason motor neurons are especially vulnerable compared with other cells is presumed to be that SMN plays additional roles in mRNA localization and translation in dendrites and axons. Muscle fiber atrophy is a secondary phenomenon resulting from loss of innervation, and as denervation followed by reinnervation repeats, characteristic chronic denervation findings appear on electromyography. Recent studies have shown that SMN deficiency activates various cellular stress pathways, including neuromuscular junction (NMJ) dysfunction, mitochondrial dysfunction, and endoplasmic reticulum stress. Evidence is also accumulating that intrinsic pathology due to SMN deficiency may exist in muscle itself, and the view has been put forward that SMA should be understood not as a purely neurogenic disease but as a combined neuromuscular disease.
SMA type II presents with symptoms between 6 and 18 months of age; patients can sit alone but cannot walk independently. Main symptoms include symmetric proximal muscle weakness (especially of the lower limbs), hypotonia, frequent respiratory infections due to respiratory muscle weakness, swallowing impairment, and weak phonation. Scoliosis progresses when maintaining a supported sitting posture is difficult and in severe cases further restricts breathing. SMA type III (Kugelberg-Welander disease) begins between 18 months and adolescence and is characterized by the ability to walk independently. Ascending proximal muscle weakness produces the Gowers sign (rising by pushing on the knees with the hands), climbing stairs and running become difficult, and walking ability may be lost over the course of the disease. Muscle cramps and fatigue are also common complaints. In type III, respiratory function is relatively better preserved than in type II, but nocturnal hypoventilation may develop with advancing age. SMA type IV (adult type) begins after age 35 and has a very slowly progressive course; most maintain independent walking and often survive without major impact on quality of life. Swallowing and speech impairment are rare in types III and IV but may occur in some. Cognitive function is preserved normally in all SMA types.
On physical examination, patients with SMA types II and III commonly show markedly reduced or absent deep tendon reflexes (DTRs). Hypotonia appears in the form of flaccid paralysis, and proximal regions (buttocks, thighs, shoulders, upper arms) are more severely involved than distal regions. Fasciculations of the tongue are sometimes observed and are an important sign of a lower motor neuron lesion. Limb fasciculations are also identified in some. In SMA type II, a fine finger tremor (polyminimyoclonus) is often observed and is known as a characteristic finding of SMA. Chest deformities may include a bell-shaped chest, rib flaring, and an abdominal breathing pattern. In advanced stages, scoliosis becomes prominent and may be accompanied by hip dislocation or ankle contractures. Skin and sensory function are normal, and there are generally no autonomic abnormalities. Cardiac function is also mostly normal, but cardiac autonomic abnormalities have been reported in some SMA types I–II. Eye movements are preserved normally. In type III, the Gowers sign, waddling gait, and lumbar lordosis are prominent.
Newborn screening (NBS) plays a key role in early detection of SMA and initiation of treatment before symptoms. In Korea, SMA was included among the newborn screening items through a Health Insurance Review & Assessment Service (HIRA) notice from 2022. As the testing method, SMN1 exon 7 deletion is detected in dried blood spots (DBS) using MLPA (Multiplex Ligation-dependent Probe Amplification) or real-time quantitative PCR (qPCR). Screening sensitivity is high at about 95% or more, but false negatives may occur in children of 2+0 carriers (2 SMN1 copies concentrated on one chromosome). When there is a family history, prenatal genetic testing (MLPA/sequencing after amniocentesis or chorionic villus sampling) is recommended. Preimplantation genetic testing (PGT-M) is also available, allowing selective transfer of embryos with respect to the SMA gene. Population carrier screening has been recognized as cost-effective and is performed in several countries; in Korea as well, couple carrier testing is offered at reproductive medicine centers. When screening is positive, confirmatory detailed genetic testing and consultation with a neurologist should be carried out immediately.
Confirmation of SMA is made by molecular genetic testing. As the first-line diagnostic test, confirmation of homozygous SMN1 exon 7 deletion using MLPA or qPCR is recommended. If this test is positive, SMN2 copy number quantification is also performed and used for phenotype prediction and treatment decisions. When the SMN1 deletion is present on only one side or no deletion is detected, compound heterozygous point mutations are sought by full SMN1 gene sequencing (Sanger or next-generation sequencing, NGS). Electrophysiological studies, nerve conduction studies (NCS) and electromyography (EMG), play a supportive role: on nerve conduction, reduced compound muscle action potentials (CMAPs) with normal motor nerve conduction velocity are characteristic, and EMG shows chronic denervation findings such as fibrillation potentials, positive sharp waves, and giant motor unit potentials. Muscle MRI is useful for identifying patterns of selective involvement of specific muscle groups. Serum creatine kinase (CK) is normal or mildly elevated. Muscle biopsy shows denervation atrophy (grouped atrophy) and reinnervation (type grouping), but is not currently essential for diagnosis. Assessment of respiratory function (spirometry, nocturnal oxygen saturation monitoring), nutritional status (weight, swallowing assessment), and orthopedic assessment (scoliosis angle) must be included as essential components of clinical management.
There are currently three approved disease-modifying therapies (DMTs) for SMA types II and III. First, nusinersen (Spinraza) is an antisense oligonucleotide (ASO) that modulates SMN2 pre-mRNA splicing to increase production of full-length functional SMN protein including exon 7, and is administered intrathecally. After 4 loading doses (days 0, 14, 28, 63), maintenance doses are given every 4 months. In SMA types II and III, 30–40% of patients show clinically meaningful improvement in motor function, and a 3-year Korean real-world study also confirmed sustained improvement in type II patients. Second, risdiplam (Evrysdi) is a small-molecule SMN2 splicing modifier that can be given orally. It is an alternative option for patients in whom intrathecal administration is difficult or not preferred. Third, onasemnogene abeparvovec (Zolgensma) is a gene replacement therapy using an AAV9 vector; under current Korean approval criteria it can be used only in children under 2 years of age (weight-based in some countries), so in most cases it is not directly applicable to adult patients with types II and III. Supportive care includes noninvasive positive-pressure ventilation (BiPAP/CPAP), cough assist devices, gastrostomy feeding, physical, occupational, and speech therapy, and orthopedic spinal fusion. A multidisciplinary approach (neurology, pulmonology, pediatrics, rehabilitation medicine, nutrition) is the standard care system.
Before the introduction of disease-modifying therapies, SMA type II patients were unable to walk independently and often had shortened life expectancy due to respiratory complications. However, since the introduction of nusinersen and risdiplam, maintenance of motor function and preservation of respiratory function have improved considerably, and functional improvements previously hard to expect are now being reported in some SMA type II patients. SMA type III patients can walk independently, and life expectancy is close to normal. However, without treatment the time to loss of walking ability depends on age at onset, and IIIa (onset at 18 months–3 years) loses walking ability earlier than IIIb (onset after 3 years). In type III patients receiving treatment, clinical real-world data confirm that the period of maintained walking ability is extended and functional decline is mitigated. The main cause of death is respiratory failure, and survival and quality of life can be greatly improved with appropriate respiratory support and ongoing medical management. The earlier treatment is started (especially when diagnosed by presymptomatic screening), the markedly better the prognosis. Cognitive function is preserved normally, so appropriate education and social participation are possible.
SMA currently uses genetic counseling, carrier screening, prenatal diagnosis, and preimplantation genetic testing (PGT-M) as established methods for primary prevention (preventing occurrence of the disease itself). Carrier screening can be considered not only when there is a family history of SMA but also for general couples planning pregnancy, and it has been rated positively in cost-effectiveness analyses. Carrier couples can understand the risk (1/4 probability of an affected child) through preconception genetic counseling and can choose PGT-M. During pregnancy, prenatal genetic diagnosis is possible by amniocentesis (15–20 weeks of gestation) or chorionic villus sampling (10–13 weeks of gestation). In terms of secondary prevention (early diagnosis and prevention of symptom worsening), newborn screening enables presymptomatic diagnosis and treatment initiation, dramatically improving prognosis. In patients already diagnosed, prevention of complications through regular respiratory function monitoring, vaccinations (influenza, pneumococcal, RSV prevention), nutritional management, and early detection and surgical correction of scoliosis is important. Because respiratory infections are a main cause of functional deterioration, appropriate vaccination and hygiene take priority over prophylactic antibiotic use.